Core Viewpoint - SciSparc Ltd. is progressing with its proposed merger with AutoMax Motors Ltd., which will enhance its portfolio in the electric vehicle sector while maintaining its focus on cannabinoid pharmaceuticals [1][2]. Group 1: Merger Details - SciSparc and AutoMax entered into a merger agreement in April 2024, where SciSparc will acquire 100% of AutoMax's share capital through a reverse merger [2]. - The merger is subject to customary closing conditions, including shareholder approvals from both companies and Israeli court approval [2]. - Special meetings for shareholder votes on the merger are scheduled for August 25, 2025, for SciSparc and August 28, 2025, for AutoMax [2]. Group 2: Regulatory Approvals - The U.S. Securities and Exchange Commission (SEC) declared effective the registration statement on Form F-4 regarding the merger on July 21, 2025 [3]. Group 3: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with drug development programs targeting Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [4]. - The company also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon [4].

24/7 Market News: Siyata Mobile Earns Verizon Frontline Verified Status, Now Protecting Communities Across All Major U.S. Networks July 22, 2025 9:13 AM EDT | Source: 24/7 Market News Denver, Colorado--(Newsfile Corp. - July 22, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Siyata Mobile (NASDAQ: SYTA), a global developer and vendor of mission-critical Push-to-Talk over Cellular (PoC) handsets and accessories, ...

Market Trends - Bitcoin and Ether rebound after last week's pullback [1] Regulatory Landscape - CFTC Commissioner Pham discusses future regulatory steps as she prepares to leave the agency [1] Corporate Actions - Tron founder Justin Sun prepares to take his company public in the U S through a reverse merger [1]

Core Viewpoint - Titan Pharmaceuticals, Inc. is moving forward with a proposed merger with TalenTec Sdn. Bhd., as indicated by the filing of a registration statement on Form F-4 with the SEC [1][2]. Group 1: Merger Details - The merger between Titan and TalenTec is structured as a "reverse merger" transaction, following a Merger Agreement established on August 19, 2024 [1]. - The Business Combination is subject to approval by Titan stockholders and is expected to close in the third quarter of 2025, although this timeline is not guaranteed [3]. Group 2: Regulatory Filings - Black Titan Corporation, the holding company for the merger, has filed the registration statement on Form F-4, which includes a preliminary proxy statement/prospectus [2][4]. - Once the registration statement is effective, a definitive Proxy Statement/Prospectus will be sent to Titan's stockholders for their vote on the Business Combination [4]. Group 3: Participant Information - Titan, TalenTec, and their respective management may be considered participants in the solicitation of proxies from Titan's stockholders regarding the merger [5]. - Detailed information about the officers and directors of both companies will be included in the registration statement and the Proxy Statement/Prospectus [5].